Hyderabad, Andhra Pradesh, India
If you are on Clopidogrel or Aspirin, there are good chances you are moving around blindfolded and paying for side effects only. This is because there is currently no better drug available, no simple and accurate measurement of clotting time exists and Doctors have no clue whether Aspirin/ Clopidogrel is actually working for you.
Mr. Sambaru Prasad, CEO, Lipicard Technologies said, "Platrol® - The new antiplatelet drug improves the efficacy by 40% over Aspirin and reduces the toxicity to almost nil. And in combination with a simple and accurate measurement to know whether you are responding, and monitoring the clotting time periodically will save you the trouble of paying for just ulcers and diarrhea only! Platrol® belongs to a new class of Novel High Therapeutic Index drugs which has completed pilot human clinical trials."
Aspirin since 1900 has been used for pain, inflammation and fever. After its antiplatelet activity was discovered in late 1980s, millions started taking it indefinitely for life-long cardio-protection.
Is the Aspirin good for cardio-protection?
--Just about 30% increase in clotting time and effectively reduces the cardiovascular deaths by only 17%,
--Over 50% suffer from toxic side effects,
--Sizable population does not respond to aspirin,
--Initial responders become non-responders later and vice versa,
--No accurate measurement to determine the response and efficacy of Aspirin.
The CAPRIE study revealed that PLAVIX® (Clopidogrel) is only about 8.7% better than Aspirin on reducing adverse cardiovascular events, with same level of toxicity as Aspirin (about 50%).
About Lipicard Technologies
Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardioprotection in collaboration with Life Enhancing Technologies LLC. USA. Platrol® is the first safe antiplatelet drug being developed for cardio-protection. Next in line is the integrated Lipid management drug for increasing HDL and lowering LDL.
PLAVIX® and Platrol® are registered trademarks of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership and Life Enhancing Technologies respectively.
Prasad Sambaru, Lipicard Technologies Limited, +91 (040) 2354 0413/ 2354 1068 sambaruprasad@lipicard.com
Source: Lipicard Technologies Limited (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.